WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Bioanalytical Systems, Inc. (NASDAQ:BASI) today (“BASi” or the “Company”) announced financial results for the second quarter of fiscal 2015.
“The second quarter and first half financial results, overall, indicate flat to slightly lower revenue growth versus the prior fiscal year. I am encouraged, however, that the long term will reflect that BASi is consistently improving our focus on providing high-quality, timely data and laboratory instruments in support of new drug discoveries and is growing the business . We have intensified our efforts to actively recruit business by sharing our full line of capabilities with potential new clients at a record high rate, presentation of scientific white papers, attendance and sponsorship at industry leading conventions and by pursuing repeat business with our extensive, satisfied long-term client base while continuing to implement operational efficiency improvements which differentiate our company from other CROs based upon innovation, client-focus and regulatory excellence,” said BASi’s President and Chief Executive Officer, Jacqueline Lemke.
“As we carry our message of high quality data, analysis and instruments to the market and deliver our studies and products on time and in full, we are creating value for not only our clients but our shareholders which will be reflected in long term revenue growth over time, expanded margins and higher cash flow,” Ms. Lemke concluded.
Second Quarter Results
For the three months ended March 31, 2015, revenues decreased 3.1% to $5,726,000 compared to $5,912,000 in the second quarter of fiscal 2014.
Service revenue for the second quarter of fiscal 2015 of $4,530,000 was essentially flat compared to $4,526,000 for the same period of the prior fiscal year. Second quarter fiscal 2015 revenues were impacted by lower Other Laboratory services revenue, partially offset by increases in the volume of Preclinical and Bioanalytical analysis revenues.
Product revenue for the second quarter of fiscal 2015 amounted to $1,196,000, a decrease of 13.7% compared to revenue of $1,386,000 for the second quarter of fiscal 2014. The decline was due to lower analytical product and other instrument sales in addition to slightly lower sales of the Culex® in vivo sampling systems.
Gross profit decreased to $1,802,000, or 31.5% of revenue, in the second quarter of fiscal 2015 compared to $2,012,000, or 34.0% of revenue, during the comparable period last fiscal year. The decline reflects the impact of lower revenue and a less favorable mix..
Operating expenses for the second quarter of fiscal 2015 decreased to $1,774,000 compared to $1,907,000 during the second quarter of fiscal 2014, primarily due to the elimination of a direct sales role in the UK and a Vice-President role in our Evansville facility,
Operating income for the second quarter of fiscal 2015 amounted to $28,000 compared to operating income of $105,000 for the second quarter of fiscal 2014, primarily due to lower revenue offset in part by lower operating expenses.
Net income was $150,000 for the second quarter of fiscal 2015. Diluted net loss, accounting for the adjustment for the change in fair value of warrant liability, was $(49,000) or $(0.01) per diluted share compared to a diluted net loss of $(219,000), or $(0.03) per diluted share, for the second quarter of fiscal 2014.
Adjusted EBITDA for the second quarter of fiscal 2015 amounted to $399,000 compared to Adjusted EBITDA for the first quarter of fiscal 2014 of $504,000.
First Half Results
For the six months ended March 31, 2015, revenue decreased 4.6% to $11,571,000 compared to $12,132,000 for the first six months of fiscal 2014. The decline was due to lower Bioanalytical and Other Laboratory revenues and a decline in other instrument sales offset in part by increases in Preclinical services and sales of the Culex®, in-vivo sampling systems. Gross profit decreased by 2.3 percentage points to $3,706,000, or 32.0% of revenue, compared to $4,157,000, or 34.3% of revenue, for the same period of the prior fiscal year. The decline was driven by a decrease in revenues which led to lower absorption of fixed costs and a change in sales mix in the Products segment. Operating income decreased to $170,000 compared to $567,000 a year earlier. The decline in operating income reflects the impact of lower revenue and lower fixed cost coverage offset in part by lower operating expenses.
Net income amounted to $332,000 for the first six months of fiscal 2015. Diluted net income, which includes the adjustment for the change in fair value of warrant liability, was $13,000 or $0.00 per diluted share for the first six months of fiscal 2015 compared to a diluted net loss of $(881,000), or $(0.11) per diluted share, for the first six months of fiscal 2014.
Adjusted EBITDA for the first six months of fiscal 2015 amounted to $949,000 compared to Adjusted EBITDA for the first six months of fiscal 2014 of $1,416,000.
Cash Used in Operating Activities
Cash provided by operating activities was $440,000 for the first six months of fiscal 2015. The Company had $536,000 in cash and cash equivalents at March 31, 2015. During the first six months, cash from operations, and cash on hand funded capital expenditures for plant, machinery and equipment of approximately $231,000 and reductions in long-term debt.
Earnings Conference Call
BASi has scheduled a conference call at 11:00 a.m. Eastern Standard Time (EDT) on May 14, 2015 to discuss the results. To participate in the call, dial 877-474-9501, participant passcode 65011068.
A simultaneous webcast of the conference call may be accessed online from the Investors tab at www.BASinc.com. The webcast will be available for replay after 2:00 p.m. (EDT) at this same internet address. For a telephone replay, dial 888-286-8010, participant passcode 27138923 after 4:00 p.m. EDT from May 14th to May 21st.
Non-GAAP to GAAP Reconciliation
This press release contains financial measures that are not calculated in accordance with generally accepted accounting principles in the United States (GAAP). The non-GAAP financial measures are adjusted EBITDA for the three and six months ended March 31, 2015 and 2014, respectively. Adjusted EBITDA refers to a financial performance measure that excludes certain income statement line items, such as interest, taxes, depreciation, and amortization. Adjusted EBITDA may also exclude certain non-cash expenses, such as stock-based compensation and the income or expense from the change in the warrant liability.
The non-GAAP financial information should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Management, however, believes that these non-GAAP financial measures, when used in conjunction with the results presented in accordance with GAAP, may provide a more complete understanding of the Company's results and may facilitate a fuller analysis of the Company's results, particularly in evaluating performance from one period to another.
Management has chosen to provide this supplemental information to investors, analysts, and other interested parties to enable them to perform additional analyses of results and to illustrate the results giving effect to the non-GAAP adjustments shown in the reconciliation. Management strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by the Company may differ from similar measures used by other companies, even when similar terms are used to identify such measures.
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more information about BASi.
This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the Company's filings with the Securities and Exchange Commission. BASi assumes no obligation to update any forward-looking statement. Actual results may vary, and could differ materially, from those anticipated, estimated, projected or expected in these forward-looking statements for a number of reasons, including, among others, the risk factors disclosed in the Company's most recent Annual Report, as filed, with the Securities and Exchange Commission.
(SEE BELOW FOR CONDENSED CONSOLIDATED FINANCIAL STATEMENTS)
BIOANALYTICAL SYSTEMS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME (LOSS)
(In thousands, except per share amounts)
|Three Months Ended||Six Months Ended|
|March 31,||March 31,|
|Service revenue||$ 4,530||$ 4,526||$ 8,928||$ 9,442|
|Cost of service revenue||3,242||3,330||6,498||6,653|
|Cost of product revenue||682||570||1,367||1,322|
|Total cost of revenue||3,924||3,900||7,865||7,975|
|Research and development||138||170||329||313|
|General and administrative||1,210||1,258||2,445||2,361|
|Total operating expenses||1,774||1,907||3,536||3,590|
|Change in fair value of warrant liability decrease (increase)||199||(200)||319||(1,161)|
|Other income (expense)||(1)||4||1||5|
|Net Income (loss) before income taxes||151||(212)||334||(874)|
|Income tax expense||1||7||2||7|
|Net Income (loss)||$ 150||$ (219)||$ 332||$ (881)|
|Other comprehensive income (loss):|
|Fair Value adjustment of interest rate swap||(15)||-||(25)|
|Foreign currency translation adjustment||51||(8)||93||(34)|
|Comprehensive Income (loss)||$ 186||$ (227)||$ 400||$ (915)|
|Basic net income (loss) per share||$ 0.02||$ (0.03)||$ 0.04||$ (0.11)|
|Diluted net income (loss) per share||$ (0.01)||$ (0.03)||$ 0.00||$ (0.11)|
|Weighted common shares outstanding:|
BIOANALYTICAL SYSTEMS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts)
|Cash and cash equivalents||$ 536||$ 981|
Trade, net of allowance of $52 at March 31, 2015 and
$54 at September 30, 2014, respectively
|Unbilled revenues and other||722||878|
|Total current assets||6,404||6,655|
|Property and equipment, net||15,451||15,949|
|Debt issue costs||108||122|
|Total assets||$ 23,008||$ 23,774|
|Liabilities and shareholders’ equity|
|Accounts payable||$ 2,550||$ 2,672|
|Income tax accruals||18||20|
|Revolving line of credit||-||202|
|Fair value of warrant liability||357||676|
|Current portion of capital lease obligation||259||279|
|Current portion of long-term debt||786||786|
|Total current liabilities||8,752||9,467|
|Fair value of interest rate swap||46||21|
|Capital lease obligation, less current portion||167||298|
|Long-term debt, less current portion||4,059||4,452|
|Preferred shares, authorized 1,000,000 shares, no par value:|
1,185 Series A shares at $1,000 stated value issued and
outstanding at March 31, 2015 and September 30,
|Common shares, no par value:|
|Authorized 19,000,000 shares; 8,076,106 issued and|
outstanding at March 31, 2015 and 8,075,335 at
September 30, 2014
|Additional paid-in capital||21,202||21,154|
|Accumulated other comprehensive income||74||7|
|Total shareholders’ equity||9,984||9,536|
|Total liabilities and shareholders’ equity||$ 23,008||$ 23,774|
|BIOANALYTICAL SYSTEMS, INC.|
|RECONCILIATION OF GAAP TO NON-GAAP EARNINGS|
|Three Months Ended||Six Months Ended|
|March 31,||March 31,|
|GAAP Net income (loss)||$ 150||$ (219)||$ 332||$ (881)|
|Add back: Interest expense||75||121||156||285|
|Depreciation and amortization||353||397||730||799|
Change in fair value of warrant liability increase
|Stock option expense||19||(2)||48||45|
|Adjusted EBITDA||$ 399||$ 504||$ 949||$ 1,416|
|Adjusted EBITDA - Earnings before interest, taxes, depreciation, amortization, stock option expenses, impairment charges and the change in the fair value of warrant liability.|